APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Primary Biliary Cirrhosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Primary Biliary Cirrhosis Drug Market Analysis and Forecast 2026-2032

Report ID 174028490219 December 2025194 pages

Choose your research edition.

Industry ResearchPrimary Biliary Cirrhosis Drug Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Primary Biliary Cirrhosis Drug Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Primary Biliary Cirrhosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Primary Biliary Cirrhosis Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Primary Biliary Cirrhosis Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Primary Biliary Cirrhosis Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Primary Biliary Cirrhosis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Primary Biliary Cirrhosis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Primary Biliary Cirrhosis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Primary Biliary Cirrhosis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Primary Biliary Cirrhosis Drug include AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH, Enanta Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., MediGene AG, NGM Biopharmaceuticals, Inc., Virobay Inc. and GlaxoSmithKline Plc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Primary Biliary Cirrhosis Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Primary Biliary Cirrhosis Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Primary Biliary Cirrhosis Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Primary Biliary Cirrhosis Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Primary Biliary Cirrhosis Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Primary Biliary Cirrhosis Drug sales, projected growth trends, production technology, application and end-user industry.

Primary Biliary Cirrhosis Drug Segment by Company

AlbireoPharma

CymaBay Therapeutics, Inc.

Dr. Falk Pharma GmbH

Enanta Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

MediGene AG

NGM Biopharmaceuticals, Inc.

Virobay Inc.

GlaxoSmithKline Plc

Johnson & Johnson

Primary Biliary Cirrhosis Drug Segment by Type

Budesonide

NGM-282

MBX-8025

GSK-2330672

FFP-104

Others

Primary Biliary Cirrhosis Drug Segment by Application

Clinic

Hospital

Others

Primary Biliary Cirrhosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Biliary Cirrhosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Primary Biliary Cirrhosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Biliary Cirrhosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Primary Biliary Cirrhosis Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Primary Biliary Cirrhosis Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Primary Biliary Cirrhosis Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Budesonide Major Manufacturers Table 3. NGM-282 Major Manufacturers Table 4. MBX-8025 Major Manufacturers Table 5. GSK-2330672 Major Manufacturers Table 6. FFP-104 Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Clinic Major Manufacturers Table 10. Hospital Major Manufacturers Table 11. Others Major Manufacturers Table 12. Primary Biliary Cirrhosis Drug Industry Trends Table 13. Primary Biliary Cirrhosis Drug Industry Drivers Table 14. Primary Biliary Cirrhosis Drug Industry Opportunities and Challenges Table 15. Primary Biliary Cirrhosis Drug Industry Restraints Table 16. Global Primary Biliary Cirrhosis Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Primary Biliary Cirrhosis Drug Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Primary Biliary Cirrhosis Drug Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2021-2026) Table 20. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2027-2032) Table 21. Global Primary Biliary Cirrhosis Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 22. Global Primary Biliary Cirrhosis Drug Sales by Region (2021-2026) & (W Units) Table 23. Global Primary Biliary Cirrhosis Drug Sales by Region (2027-2032) & (W Units) Table 24. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2021-2026) Table 25. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2027-2032) Table 26. Global Primary Biliary Cirrhosis Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Primary Biliary Cirrhosis Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Primary Biliary Cirrhosis Drug Sales Market Share by Manufacturers (2021-2026) Table 30. Global Primary Biliary Cirrhosis Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Primary Biliary Cirrhosis Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Primary Biliary Cirrhosis Drug Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Primary Biliary Cirrhosis Drug Manufacturers, Product Type & Application Table 34. Global Primary Biliary Cirrhosis Drug Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Primary Biliary Cirrhosis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Primary Biliary Cirrhosis Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Primary Biliary Cirrhosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Primary Biliary Cirrhosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2021-2026) Table 41. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2027-2032) Table 42. Global Primary Biliary Cirrhosis Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 43. Global Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (W Units) Table 44. Global Primary Biliary Cirrhosis Drug Sales by Type (2027-2032) & (W Units) Table 45. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2021-2026) Table 46. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2027-2032) Table 47. Global Primary Biliary Cirrhosis Drug Price by Type (2021-2026) & (US$/Unit) Table 48. Global Primary Biliary Cirrhosis Drug Price by Type (2027-2032) & (US$/Unit) Table 49. Global Primary Biliary Cirrhosis Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Primary Biliary Cirrhosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Primary Biliary Cirrhosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2021-2026) Table 53. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2027-2032) Table 54. Global Primary Biliary Cirrhosis Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 55. Global Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (W Units) Table 56. Global Primary Biliary Cirrhosis Drug Sales by Application (2027-2032) & (W Units) Table 57. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2021-2026) Table 58. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2027-2032) Table 59. Global Primary Biliary Cirrhosis Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Primary Biliary Cirrhosis Drug Price by Application (2027-2032) & (US$/Unit) Table 61. AlbireoPharma Company Information Table 62. AlbireoPharma Business Overview Table 63. AlbireoPharma Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio Table 65. AlbireoPharma Recent Development Table 66. CymaBay Therapeutics, Inc. Company Information Table 67. CymaBay Therapeutics, Inc. Business Overview Table 68. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 70. CymaBay Therapeutics, Inc. Recent Development Table 71. Dr. Falk Pharma GmbH Company Information Table 72. Dr. Falk Pharma GmbH Business Overview Table 73. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio Table 75. Dr. Falk Pharma GmbH Recent Development Table 76. Enanta Pharmaceuticals, Inc. Company Information Table 77. Enanta Pharmaceuticals, Inc. Business Overview Table 78. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 80. Enanta Pharmaceuticals, Inc. Recent Development Table 81. Intercept Pharmaceuticals, Inc. Company Information Table 82. Intercept Pharmaceuticals, Inc. Business Overview Table 83. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 85. Intercept Pharmaceuticals, Inc. Recent Development Table 86. MediGene AG Company Information Table 87. MediGene AG Business Overview Table 88. MediGene AG Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio Table 90. MediGene AG Recent Development Table 91. NGM Biopharmaceuticals, Inc. Company Information Table 92. NGM Biopharmaceuticals, Inc. Business Overview Table 93. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 95. NGM Biopharmaceuticals, Inc. Recent Development Table 96. Virobay Inc. Company Information Table 97. Virobay Inc. Business Overview Table 98. Virobay Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Virobay Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 100. Virobay Inc. Recent Development Table 101. GlaxoSmithKline Plc Company Information Table 102. GlaxoSmithKline Plc Business Overview Table 103. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio Table 105. GlaxoSmithKline Plc Recent Development Table 106. Johnson & Johnson Company Information Table 107. Johnson & Johnson Business Overview Table 108. Johnson & Johnson Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio Table 110. Johnson & Johnson Recent Development Table 111. North America Primary Biliary Cirrhosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 112. North America Primary Biliary Cirrhosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 113. North America Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (W Units) Table 114. North America Primary Biliary Cirrhosis Drug Sales by Type (2027-2032) & (W Units) Table 115. North America Primary Biliary Cirrhosis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 116. North America Primary Biliary Cirrhosis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 117. North America Primary Biliary Cirrhosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 118. North America Primary Biliary Cirrhosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 119. North America Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (W Units) Table 120. North America Primary Biliary Cirrhosis Drug Sales by Application (2027-2032) & (W Units) Table 121. North America Primary Biliary Cirrhosis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 122. North America Primary Biliary Cirrhosis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 123. North America Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. North America Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 125. North America Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 126. North America Primary Biliary Cirrhosis Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 127. North America Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 128. North America Primary Biliary Cirrhosis Drug Sales by Country (2027-2032) & (W Units) Table 129. North America Primary Biliary Cirrhosis Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 130. North America Primary Biliary Cirrhosis Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 131. United States Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 132. Canada Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 133. Europe Primary Biliary Cirrhosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 134. Europe Primary Biliary Cirrhosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 135. Europe Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (W Units) Table 136. Europe Primary Biliary Cirrhosis Drug Sales by Type (2027-2032) & (W Units) Table 137. Europe Primary Biliary Cirrhosis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 138. Europe Primary Biliary Cirrhosis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 139. Europe Primary Biliary Cirrhosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 140. Europe Primary Biliary Cirrhosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 141. Europe Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (W Units) Table 142. Europe Primary Biliary Cirrhosis Drug Sales by Application (2027-2032) & (W Units) Table 143. Europe Primary Biliary Cirrhosis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 144. Europe Primary Biliary Cirrhosis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 145. Europe Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. Europe Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 147. Europe Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 148. Europe Primary Biliary Cirrhosis Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 149. Europe Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 150. Europe Primary Biliary Cirrhosis Drug Sales by Country (2027-2032) & (W Units) Table 151. Europe Primary Biliary Cirrhosis Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 152. Europe Primary Biliary Cirrhosis Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 153. Germany Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 154. France Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 155. U.K. Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 156. Italy Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 157. Netherlands Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 158. Nordic Countries Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 159. China Primary Biliary Cirrhosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 160. China Primary Biliary Cirrhosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 161. China Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (W Units) Table 162. China Primary Biliary Cirrhosis Drug Sales by Type (2027-2032) & (W Units) Table 163. China Primary Biliary Cirrhosis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 164. China Primary Biliary Cirrhosis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 165. China Primary Biliary Cirrhosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 166. China Primary Biliary Cirrhosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 167. China Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (W Units) Table 168. China Primary Biliary Cirrhosis Drug Sales by Application (2027-2032) & (W Units) Table 169. China Primary Biliary Cirrhosis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 170. China Primary Biliary Cirrhosis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 171. Asia Primary Biliary Cirrhosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 172. Asia Primary Biliary Cirrhosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 173. Asia Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (W Units) Table 174. Asia Primary Biliary Cirrhosis Drug Sales by Type (2027-2032) & (W Units) Table 175. Asia Primary Biliary Cirrhosis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 176. Asia Primary Biliary Cirrhosis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 177. Asia Primary Biliary Cirrhosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 178. Asia Primary Biliary Cirrhosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 179. Asia Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (W Units) Table 180. Asia Primary Biliary Cirrhosis Drug Sales by Application (2027-2032) & (W Units) Table 181. Asia Primary Biliary Cirrhosis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 182. Asia Primary Biliary Cirrhosis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 183. Asia Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 184. Asia Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 185. Asia Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 186. Asia Primary Biliary Cirrhosis Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 187. Asia Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 188. Asia Primary Biliary Cirrhosis Drug Sales by Country (2027-2032) & (W Units) Table 189. Asia Primary Biliary Cirrhosis Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 190. Asia Primary Biliary Cirrhosis Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 191. Japan Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 192. South Korea Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 193. India Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 194. Australia Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 195. China Taiwan Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 196. Southeast Asia Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 197. SAMEA Primary Biliary Cirrhosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 198. SAMEA Primary Biliary Cirrhosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 199. SAMEA Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (W Units) Table 200. SAMEA Primary Biliary Cirrhosis Drug Sales by Type (2027-2032) & (W Units) Table 201. SAMEA Primary Biliary Cirrhosis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 202. SAMEA Primary Biliary Cirrhosis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 203. SAMEA Primary Biliary Cirrhosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 204. SAMEA Primary Biliary Cirrhosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 205. SAMEA Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (W Units) Table 206. SAMEA Primary Biliary Cirrhosis Drug Sales by Application (2027-2032) & (W Units) Table 207. SAMEA Primary Biliary Cirrhosis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 208. SAMEA Primary Biliary Cirrhosis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 209. SAMEA Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 210. SAMEA Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 211. SAMEA Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 212. SAMEA Primary Biliary Cirrhosis Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 213. SAMEA Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 214. SAMEA Primary Biliary Cirrhosis Drug Sales by Country (2027-2032) & (W Units) Table 215. SAMEA Primary Biliary Cirrhosis Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 216. SAMEA Primary Biliary Cirrhosis Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 217. Brazil Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 218. Argentina Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 219. Chile Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 220. Colombia Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 221. Peru Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 222. Saudi Arabia Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 223. Israel Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 224. UAE Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 225. Turkey Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 226. Iran Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 227. Egypt Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Table 228. Key Raw Materials Table 229. Raw Materials Key Suppliers Table 230. Primary Biliary Cirrhosis Drug Distributors List Table 231. Primary Biliary Cirrhosis Drug Customers List Table 232. Research Programs/Design for This Report Table 233. Authors List of This Report Table 234. Secondary Sources Table 235. Primary Sources List of Figures Figure 1. Primary Biliary Cirrhosis Drug Image Figure 2. Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Primary Biliary Cirrhosis Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Budesonide Image Figure 5. NGM-282 Image Figure 6. MBX-8025 Image Figure 7. GSK-2330672 Image Figure 8. FFP-104 Image Figure 9. Others Image Figure 10. Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Primary Biliary Cirrhosis Drug Market Size Share 2021 VS 2025 VS 2032 Figure 12. Clinic Image Figure 13. Hospital Image Figure 14. Others Image Figure 15. Global Primary Biliary Cirrhosis Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Figure 17. Global Primary Biliary Cirrhosis Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2021-2032) Figure 20. Global Primary Biliary Cirrhosis Drug Sales (2021-2032) & (W Units) Figure 21. Global Primary Biliary Cirrhosis Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 22. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Primary Biliary Cirrhosis Drug Sales YoY (2021-2032) & (W Units) Figure 24. Europe Primary Biliary Cirrhosis Drug Sales YoY (2021-2032) & (W Units) Figure 25. China Primary Biliary Cirrhosis Drug Sales YoY (2021-2032) & (W Units) Figure 26. Asia (Excluding China) Primary Biliary Cirrhosis Drug Sales YoY (2021-2032) & (W Units) Figure 27. South America, Middle East and Africa Primary Biliary Cirrhosis Drug Sales YoY (2021-2032) & (W Units) Figure 28. Global Primary Biliary Cirrhosis Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Primary Biliary Cirrhosis Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Primary Biliary Cirrhosis Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2021-2032) Figure 34. Global Primary Biliary Cirrhosis Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 35. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2021-2032) Figure 37. Global Primary Biliary Cirrhosis Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2021-2032) Figure 40. Global Primary Biliary Cirrhosis Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 41. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2021-2032) Figure 43. North America Primary Biliary Cirrhosis Drug Revenue Share by Type (2021-2032) Figure 44. North America Primary Biliary Cirrhosis Drug Sales Share by Type (2021-2032) Figure 45. North America Primary Biliary Cirrhosis Drug Revenue Share by Application (2021-2032) Figure 46. North America Primary Biliary Cirrhosis Drug Sales Share by Application (2021-2032) Figure 47. North America Primary Biliary Cirrhosis Drug Revenue Share by Country (2021-2032) Figure 48. North America Primary Biliary Cirrhosis Drug Sales Share by Country (2021-2032) Figure 49. Europe Primary Biliary Cirrhosis Drug Revenue Share by Type (2021-2032) Figure 50. Europe Primary Biliary Cirrhosis Drug Sales Share by Type (2021-2032) Figure 51. Europe Primary Biliary Cirrhosis Drug Revenue Share by Application (2021-2032) Figure 52. Europe Primary Biliary Cirrhosis Drug Sales Share by Application (2021-2032) Figure 53. Europe Primary Biliary Cirrhosis Drug Revenue Share by Country (2021-2032) Figure 54. Europe Primary Biliary Cirrhosis Drug Sales Share by Country (2021-2032) Figure 55. China Primary Biliary Cirrhosis Drug Revenue Share by Type (2021-2032) Figure 56. China Primary Biliary Cirrhosis Drug Sales Share by Type (2021-2032) Figure 57. China Primary Biliary Cirrhosis Drug Revenue Share by Application (2021-2032) Figure 58. China Primary Biliary Cirrhosis Drug Sales Share by Application (2021-2032) Figure 59. Asia Primary Biliary Cirrhosis Drug Revenue Share by Type (2021-2032) Figure 60. Asia Primary Biliary Cirrhosis Drug Sales Share by Type (2021-2032) Figure 61. Asia Primary Biliary Cirrhosis Drug Revenue Share by Application (2021-2032) Figure 62. Asia Primary Biliary Cirrhosis Drug Sales Share by Application (2021-2032) Figure 63. Asia Primary Biliary Cirrhosis Drug Revenue Share by Country (2021-2032) Figure 64. Asia Primary Biliary Cirrhosis Drug Sales Share by Country (2021-2032) Figure 65. SAMEA Primary Biliary Cirrhosis Drug Revenue Share by Type (2021-2032) Figure 66. SAMEA Primary Biliary Cirrhosis Drug Sales Share by Type (2021-2032) Figure 67. SAMEA Primary Biliary Cirrhosis Drug Revenue Share by Application (2021-2032) Figure 68. SAMEA Primary Biliary Cirrhosis Drug Sales Share by Application (2021-2032) Figure 69. SAMEA Primary Biliary Cirrhosis Drug Revenue Share by Country (2021-2032) Figure 70. SAMEA Primary Biliary Cirrhosis Drug Sales Share by Country (2021-2032) Figure 71. Primary Biliary Cirrhosis Drug Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Primary Biliary Cirrhosis Drug Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Budesonide
  • NGM-282
  • MBX-8025
  • GSK-2330672
  • FFP-104
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • AlbireoPharma
  • CymaBay Therapeutics, Inc.
  • Dr. Falk Pharma GmbH
  • Enanta Pharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • MediGene AG
  • NGM Biopharmaceuticals, Inc.
  • Virobay Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Primary Biliary Cirrhosis Drug Market by Type
  3. 1.2.1 Global Primary Biliary Cirrhosis Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Budesonide
  5. 1.2.3 NGM-282
  6. 1.2.4 MBX-8025
  7. 1.2.5 GSK-2330672
  8. 1.2.6 FFP-104
  9. 1.2.7 Others
  10. 1.3 Primary Biliary Cirrhosis Drug Market by Application
  11. 1.3.1 Global Primary Biliary Cirrhosis Drug Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Clinic
  13. 1.3.3 Hospital
  14. 1.3.4 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Primary Biliary Cirrhosis Drug Market Dynamics
  1. 2.1 Primary Biliary Cirrhosis Drug Industry Trends
  2. 2.2 Primary Biliary Cirrhosis Drug Industry Drivers
  3. 2.3 Primary Biliary Cirrhosis Drug Industry Opportunities and Challenges
  4. 2.4 Primary Biliary Cirrhosis Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Primary Biliary Cirrhosis Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Primary Biliary Cirrhosis Drug Revenue by Region
  3. 3.2.1 Global Primary Biliary Cirrhosis Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Primary Biliary Cirrhosis Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Primary Biliary Cirrhosis Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Primary Biliary Cirrhosis Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Primary Biliary Cirrhosis Drug Sales by Region
  9. 3.4.1 Global Primary Biliary Cirrhosis Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Primary Biliary Cirrhosis Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Primary Biliary Cirrhosis Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Primary Biliary Cirrhosis Drug Revenue by Manufacturers
  2. 4.1.1 Global Primary Biliary Cirrhosis Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Primary Biliary Cirrhosis Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Primary Biliary Cirrhosis Drug Sales by Manufacturers
  6. 4.2.1 Global Primary Biliary Cirrhosis Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Primary Biliary Cirrhosis Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Primary Biliary Cirrhosis Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Primary Biliary Cirrhosis Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Primary Biliary Cirrhosis Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Primary Biliary Cirrhosis Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Primary Biliary Cirrhosis Drug Manufacturers, Product Type & Application
  13. 4.7 Global Primary Biliary Cirrhosis Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Primary Biliary Cirrhosis Drug Market CR5 and HHI
  16. 4.8.2 2025 Primary Biliary Cirrhosis Drug Tier 1, Tier 2, and Tier 3
5 Primary Biliary Cirrhosis Drug Market by Type
  1. 5.1 Global Primary Biliary Cirrhosis Drug Revenue by Type
  2. 5.1.1 Global Primary Biliary Cirrhosis Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Primary Biliary Cirrhosis Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Primary Biliary Cirrhosis Drug Sales by Type
  6. 5.2.1 Global Primary Biliary Cirrhosis Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Primary Biliary Cirrhosis Drug Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Primary Biliary Cirrhosis Drug Price by Type
6 Primary Biliary Cirrhosis Drug Market by Application
  1. 6.1 Global Primary Biliary Cirrhosis Drug Revenue by Application
  2. 6.1.1 Global Primary Biliary Cirrhosis Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Primary Biliary Cirrhosis Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Primary Biliary Cirrhosis Drug Sales by Application
  6. 6.2.1 Global Primary Biliary Cirrhosis Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Primary Biliary Cirrhosis Drug Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Primary Biliary Cirrhosis Drug Price by Application
7 Company Profiles
  1. 7.1 AlbireoPharma
  2. 7.1.1 AlbireoPharma Company Information
  3. 7.1.2 AlbireoPharma Business Overview
  4. 7.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio
  6. 7.1.5 AlbireoPharma Recent Developments
  7. 7.2 CymaBay Therapeutics, Inc.
  8. 7.2.1 CymaBay Therapeutics, Inc. Company Information
  9. 7.2.2 CymaBay Therapeutics, Inc. Business Overview
  10. 7.2.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  12. 7.2.5 CymaBay Therapeutics, Inc. Recent Developments
  13. 7.3 Dr. Falk Pharma GmbH
  14. 7.3.1 Dr. Falk Pharma GmbH Company Information
  15. 7.3.2 Dr. Falk Pharma GmbH Business Overview
  16. 7.3.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio
  18. 7.3.5 Dr. Falk Pharma GmbH Recent Developments
  19. 7.4 Enanta Pharmaceuticals, Inc.
  20. 7.4.1 Enanta Pharmaceuticals, Inc. Company Information
  21. 7.4.2 Enanta Pharmaceuticals, Inc. Business Overview
  22. 7.4.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  24. 7.4.5 Enanta Pharmaceuticals, Inc. Recent Developments
  25. 7.5 Intercept Pharmaceuticals, Inc.
  26. 7.5.1 Intercept Pharmaceuticals, Inc. Company Information
  27. 7.5.2 Intercept Pharmaceuticals, Inc. Business Overview
  28. 7.5.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  30. 7.5.5 Intercept Pharmaceuticals, Inc. Recent Developments
  31. 7.6 MediGene AG
  32. 7.6.1 MediGene AG Company Information
  33. 7.6.2 MediGene AG Business Overview
  34. 7.6.3 MediGene AG Primary Biliary Cirrhosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio
  36. 7.6.5 MediGene AG Recent Developments
  37. 7.7 NGM Biopharmaceuticals, Inc.
  38. 7.7.1 NGM Biopharmaceuticals, Inc. Company Information
  39. 7.7.2 NGM Biopharmaceuticals, Inc. Business Overview
  40. 7.7.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  42. 7.7.5 NGM Biopharmaceuticals, Inc. Recent Developments
  43. 7.8 Virobay Inc.
  44. 7.8.1 Virobay Inc. Company Information
  45. 7.8.2 Virobay Inc. Business Overview
  46. 7.8.3 Virobay Inc. Primary Biliary Cirrhosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Virobay Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  48. 7.8.5 Virobay Inc. Recent Developments
  49. 7.9 GlaxoSmithKline Plc
  50. 7.9.1 GlaxoSmithKline Plc Company Information
  51. 7.9.2 GlaxoSmithKline Plc Business Overview
  52. 7.9.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio
  54. 7.9.5 GlaxoSmithKline Plc Recent Developments
  55. 7.10 Johnson & Johnson
  56. 7.10.1 Johnson & Johnson Company Information
  57. 7.10.2 Johnson & Johnson Business Overview
  58. 7.10.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio
  60. 7.10.5 Johnson & Johnson Recent Developments
8 North America
  1. 8.1 North America Primary Biliary Cirrhosis Drug Market Size by Type
  2. 8.1.1 North America Primary Biliary Cirrhosis Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Primary Biliary Cirrhosis Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Primary Biliary Cirrhosis Drug Price by Type (2021-2032)
  5. 8.2 North America Primary Biliary Cirrhosis Drug Market Size by Application
  6. 8.2.1 North America Primary Biliary Cirrhosis Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Primary Biliary Cirrhosis Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Primary Biliary Cirrhosis Drug Price by Application (2021-2032)
  9. 8.3 North America Primary Biliary Cirrhosis Drug Market Size by Country
  10. 8.3.1 North America Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Primary Biliary Cirrhosis Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Primary Biliary Cirrhosis Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Primary Biliary Cirrhosis Drug Market Size by Type
  2. 9.1.1 Europe Primary Biliary Cirrhosis Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Primary Biliary Cirrhosis Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Primary Biliary Cirrhosis Drug Price by Type (2021-2032)
  5. 9.2 Europe Primary Biliary Cirrhosis Drug Market Size by Application
  6. 9.2.1 Europe Primary Biliary Cirrhosis Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Primary Biliary Cirrhosis Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Primary Biliary Cirrhosis Drug Price by Application (2021-2032)
  9. 9.3 Europe Primary Biliary Cirrhosis Drug Market Size by Country
  10. 9.3.1 Europe Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Primary Biliary Cirrhosis Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Primary Biliary Cirrhosis Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Primary Biliary Cirrhosis Drug Market Size by Type
  2. 10.1.1 China Primary Biliary Cirrhosis Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Primary Biliary Cirrhosis Drug Sales by Type (2021-2032)
  4. 10.1.3 China Primary Biliary Cirrhosis Drug Price by Type (2021-2032)
  5. 10.2 China Primary Biliary Cirrhosis Drug Market Size by Application
  6. 10.2.1 China Primary Biliary Cirrhosis Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Primary Biliary Cirrhosis Drug Sales by Application (2021-2032)
  8. 10.2.3 China Primary Biliary Cirrhosis Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Primary Biliary Cirrhosis Drug Market Size by Type
  2. 11.1.1 Asia Primary Biliary Cirrhosis Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Primary Biliary Cirrhosis Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Primary Biliary Cirrhosis Drug Price by Type (2021-2032)
  5. 11.2 Asia Primary Biliary Cirrhosis Drug Market Size by Application
  6. 11.2.1 Asia Primary Biliary Cirrhosis Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Primary Biliary Cirrhosis Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Primary Biliary Cirrhosis Drug Price by Application (2021-2032)
  9. 11.3 Asia Primary Biliary Cirrhosis Drug Market Size by Country
  10. 11.3.1 Asia Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Primary Biliary Cirrhosis Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Primary Biliary Cirrhosis Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Primary Biliary Cirrhosis Drug Market Size by Type
  2. 12.1.1 SAMEA Primary Biliary Cirrhosis Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Primary Biliary Cirrhosis Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Primary Biliary Cirrhosis Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Primary Biliary Cirrhosis Drug Market Size by Application
  6. 12.2.1 SAMEA Primary Biliary Cirrhosis Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Primary Biliary Cirrhosis Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Primary Biliary Cirrhosis Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Primary Biliary Cirrhosis Drug Market Size by Country
  10. 12.3.1 SAMEA Primary Biliary Cirrhosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Primary Biliary Cirrhosis Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Primary Biliary Cirrhosis Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Primary Biliary Cirrhosis Drug Value Chain Analysis
  2. 13.1.1 Primary Biliary Cirrhosis Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Primary Biliary Cirrhosis Drug Production Mode & Process
  6. 13.2 Primary Biliary Cirrhosis Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Primary Biliary Cirrhosis Drug Distributors
  9. 13.2.3 Primary Biliary Cirrhosis Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst